Children with frequent recurrent episodes of otitis media may have a deficient IgG2 antibody response to polysaccharide antigens. Five otitis-prone children were vaccinated with heptavalent pneumococcal conjugate vaccine. While all had an IgG1 antibody response to all pneumococcal serotypes included in the conjugate vaccine, the IgG2 response, especially to serotypes 6B, 9V, 19F, and 23F, was poor. However, vaccination with a 23-valent polysaccharide vaccine 6 months after conjugate vaccination induced an 11.5-to 163-fold increase in IgG2 anti-polysaccharide antibody titers. Thus, an IgG2 polysaccharide antibody deficiency can be overcome by priming with a pneumococcal conjugate vaccine followed by a booster with a polyvalent polysaccharide vaccine.
Acute otitis media (AOM) is the most frequent bacterial infection in infants and young children. By age 3 years, 71% of children have had one or more episodes of AOM [1] . Streptococcus pneumoniae is the main pathogen in bacterial AOM, involved in at least 50%-60% of the cases. The defense against infections with these bacteria, characterized by their polysaccharide capsule, depends primarily on antibodies against the capsular polysaccharide.
The peak incidence of childhood AOM occurs at age 6-18 months, which matches the period after maternally derived antibodies have disappeared and before the onset of antibody formation to polysaccharide antigens. Up to 5% of all children are highly susceptible to infections with S. pneumoniae, manifested in frequently recurrent episodes of AOM. This condition, termed otitis-prone, can persist beyond age 2 years. Otitis-prone children are thought to be immunologically different from agematched healthy children in their inability to mount an adequate IgG2 antibody response to S. pneumoniae [2] .
We previously described a group of children with frequent recurrent mucosal respiratory tract infections. These children showed low-to-absent IgG2 and/or IgA pneumococcal polysaccharide antibody responses after vaccination with pneumococcal polysaccharide (PnPS) vaccine, despite normal serum IgG2 and IgA immunoglobulin levels [3] . Recently, D'Hooghe et al. (unpublished data) observed in a group of patients with otitis media with effusion significantly lower IgG2 and IgA pneumococcal polysaccharide antibody responses after vaccination with PnPS vaccine than in age-matched, healthy controls. In all three studies, the IgG1 polysaccharide antibody response was normal. These observations suggest that deficient IgG2 response to PnPS vaccine is associated with a clinical state manifested with recurrent otitis media. A causal relationship has not been established, however, and the poor IgG2 response to pneumococcal vaccine also may be a marker for another immunologic abnormality that renders these children prone to recurrent respiratory tract infections.
Polysaccharide conjugate vaccines have been developed to change the nature of the anti-polysaccharide antibody response into a T cell-dependent response and thus induce responsivity early in life. Pneumococcal conjugate vaccines (PCV) are immunogenic in infants [4] [5] [6] and induce immunologic memory [6] . PCV induce primarily an IgG1 type anti-polysaccharide antibody response [6] . It remains to be determined whether IgG1 antibodies alone will be sufficient to prevent mucosal infections like AOM in an otitis-prone childhood population. It is possible that the induction of IgG2 or IgA pneumococcal polysaccharide antibodies may be necessary for optimal protection against mucosal respiratory tract infections.
On the basis of the results of a study by O'Brien et al. [6] and of our unpublished observations, we hypothesized that priming with a conjugate vaccine, followed by vaccination with a PnPS vaccine, might induce an increased IgG antibody response and favor a shift toward an IgG2 type antibody response. Here we present the results of a preliminary study in 5 otitis-prone children vaccinated with a PCV, followed by booster vaccination with a PnPS vaccine.
Methods
Patient population. The children in this study were referred to the Department of Immunology of our hospital by their pediatri- NOTE. Antibody levels to pneumococcal serotypes included in PCV (4, 6B, 9V, 14, 18C, 19F, and 23F) before (pre) and after (post) vaccination with PCV or PnPS. Fold increase (FI) is calculated by dividing post-and prevaccination antibody titers. Geometric mean antibody titers and fold increase are indicated. NOTE. Antibody levels to pneumococcal serotypes 1 and 12 (not included in PCV) before (pre) and after (post) vaccination with PCV or PnPS. Fold increase (FI) is calculated by dividing post-and prevaccination antibody titers. Geometric mean antibody titers and fold increase are indicated.
cian or otolaryngologist because of recurrent AOM with otorrhea (у6-8 episodes per year). All 5 children were Caucasian and 12 years old (2.1-12.5 years at time of conjugate vaccination). Their AOM episodes were characterized by signs of pain, irritability, new otorrhea, and additional symptoms such as fever (138.5ЊC) and concomitant signs of upper respiratory tract infection. The diagnosis AOM was confirmed by otoscopic signs typical for AOM [7] . None of the children had anatomic abnormalities or recognized disease entities such as cystic fibrosis or granulocytopenia. Total serum immunoglobulin levels (IgG and IgG subclasses, IgA, and IgM) were normal for age. In 2 subjects, total IgE levels were elevated (300 and 53 U/L, respectively). Complement activity was normal as were antibody responses to tetanus and diphtheria toxoid. Two children had previously (2 and 7.5 years before conjugate vaccine) received a 23-valent PnPS vaccine (Pneumovax; Merck, Sharp & Dohme, Haarlem, The Netherlands), containing 25 mg of purified type-specific capsular polysaccharides of 23 pneumococcal serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,  17F, 18C, 19A, 19F, Determination of type specific polysaccharide antibodies. IgG1-, IgG2-, IgA-, and IgM-type serum antibody levels to the 7 pneumococcal polysaccharides included in the conjugate vaccine and to 2 pneumococcal polysaccharides not included in the PCV (serotypes 1 and 12) were measured by ELISA as described previously [3] . Pre-and postvaccination serum samples were analyzed simultaneously. All serum samples were preincubated overnight with excess free common cell wall polysaccharide (CPS), a procedure that neutralized anti-CPS antibodies. Alkaline phosphatase-labeled goat anti-human IgA (2941; Tago, Burlingame, CA) and peroxidase-labeled, subclass-specific murine anti-human IgG1 (MH161-1ME) or IgG2 (MH162-1ME) monoclonals (Central Laboratory of the Red Cross Blood Transfusion Service, Amsterdam) were used as detecting antibodies. A standard serum from a normal nonvaccinated adult was included in every ELISA run as a control.
Antibody concentrations of patient samples were expressed relative to a reference adult hyperimmune plasma pool [8] . Antibody concentrations in the plasma pool were assigned 100 U/mL (100%) for each serotype. The lower limit of detection is 0.1 U/mL. Antibody levels are expressed as geometric means. Fold increase in antibody titers is calculated by dividing individual post-and preimmunization titers; geometric mean values are given.
Results

Pneumococcal antibody responses after PCV.
Vaccination with PCV induced a significant (2-to 23-fold) increase in IgG1 antibody levels for all pneumococcal serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F; see table 1). Geometric mean IgG2 anti-pneumococcal polysaccharide antibody levels after vaccination with PCV remained !20 U/mL for all serotypes, except for serotype 14. One child mounted an extremely high IgG2 anti-PS14 antibody response (1968 U/mL). The IgA antibody response was 120 U/mL for 3 of the serotypes included in the PCV. As expected, antibody levels to pneumococcal serotypes not included in the PCV (serotypes 1 and 12) did not change (table 2) .
Antibody responses after PnPS vaccination. Six months after vaccination with the PCV, the subjects were booster vac- cinated with a 23-valent PnPS vaccine. This booster vaccination with nonconjugated polysaccharides induced a clear-cut IgG2 antibody response, which is illustrated for serotypes 9V and 23F in figure 1 . Among the 7 PCV serotypes, post-PnPs IgG2 titers to 6B and 23F were the lowest, although the fold increase in IgG2 antibodies was 110 for serotype 6B and 17 for serotype 23F (table 1) . Booster vaccination with the PnPS vaccine also induced a substantial IgA antibody response and a further increase in IgG1 pneumococcal polysaccharide antibodies ( figure  1, table 1 ). The antibody titers reached after vaccination with PnPS against serotypes not included in the PCV (1 and 12) were considerably lower (table 2) .
Discussion
Polyvalent PnPS vaccines normally induce IgM, IgG1, IgG2, and IgA antibodies. Of these, especially in adults and older children, IgG2 is the predominant isotype [9] . Although polysaccharide antibodies confer protection against infections with encapsulated bacteria, the actual contribution of the various isotypes to host defense is unknown. Patients with an IgA or IgG2 deficiency have an increased susceptibility for mucosal infections with encapsulated bacteria [10, 11] . We previously described a childhood population with recurrent mucosal upper respiratory tract infections in which encapsulated bacteria like S. pneumoniae are a major pathogen. Striking was the low-toabsent IgG2 and IgA antibody responses: 43% of all children had defective IgG2 antibody responses, and 22% also low IgA antibody responses after vaccination with the 23-valent PnPS vaccine [3] . Therefore, the inability to make IgG2 and IgA type pneumococcal polysaccharide antibodies appears to define a clinical entity of high susceptibility for mucosal infections with encapsulated bacteria.
The frequent occurrence of infections with encapsulated bacteria in infants and young children reflects the ontogeny of the components of host defense [12, 13] . The existing polysaccharide vaccines are of limited use in infants and young children because for many polysaccharide antigens, adequate antibody titers are not attained until age у18-24 months [11] . However, covalent conjugation of a protein carrier to bacterial capsular polysaccharides induces upon immunization a T cell-dependent antibody response and priming for an anamnestic or secondary response [11, 14, 15] . PCVs are safe and immunogenic in healthy infants and young children [16] [17] [18] and prime the vaccinees to respond to a nonconjugated polysaccharide vaccine [17, 18] . Furthermore, secondary immunization with PnPS vaccine after priming with a conjugate vaccine elicited in healthy infants and young children an increase in both IgG1 and IgG2 subclasses [19] .
In children with recurrent mucosal respiratory tract infections, an aberrant response to PnPS vaccines is frequently observed [3, 20] . The data in this study indicate that the specific IgG2 anti-polysaccharide antibody deficiency in patients with recurrent respiratory tract infections can be overcome by vaccination with PCV followed by booster vaccination with a polyvalent PnPS vaccine. Thus, otitis-prone children and others at risk for invasive infections with encapsulated bacteria might benefit from such a vaccination schedule.
The mechanism of how a PCV can prime for a PnPS-inducible IgG2 response is unknown. It would be desirable if priming would also occur for serotypes not included in the PCV. Our data on the PnPS booster vaccination-induced IgG2 response to serotypes 1 and 12 are not conclusive, and a larger group of patients plus a control group not primed with PCV are needed to address this issue.
